New test may expand who benefits from ovarian cancer drug
NCT ID NCT04780945
First seen Feb 18, 2026 · Last updated Jun 16, 2026 · Updated 14 times
Summary
This study tested a new lab method (RAD51 assay) to see if it could better predict which patients with recurrent ovarian cancer would respond to the drug olaparib. The goal was to find more patients who could benefit, beyond those with BRCA gene mutations. The study was stopped early and enrolled 27 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medical Center
Rotterdam, Netherlands
-
Leiden University Medical Center
Leiden, 2300RC, Netherlands
-
University Medical Center Groningen
Groningen, Netherlands
Conditions
Explore the condition pages connected to this study.